계명대학교 의학도서관 Repository

A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group

Metadata Downloads
Affiliated Author(s)
송홍석
Alternative Author(s)
Song, Hong Suk
Journal Title
Oncologist
ISSN
1083-7159
Issued Date
2014
Abstract
Background. Combination chemotherapy consisting of ifosfamide,
methotrexate, etoposide, and prednisolone (IMEP) was
active as first-line and second-line treatment for extranodal
natural killer/T-cell lymphoma (NTCL).
Methods. Forty-four patients with chemo-na¨ıve stage I/IINTCL
were enrolled in a prospective, multicenter, phase II study
and received six cycles of IMEP (ifosfamide 1.5 g/m2 on days
1–3; methotrextate 30 mg/m2 on days 3 and 10; etoposide
100 mg/m2 on days 1–3; and prednisolone 60 mg/m2 per day
on days 1–5) followed by involved field radiotherapy (IFRT).
Results. Overall response rates were 73% (complete remission
[CR] in 11 of 41 evaluable patients [27%]) after IMEP chemotherapy
and 78% (CR 18 of 27 evaluable patients [67%]) after
IMEP followed by IFRT. Neutropenia and thrombocytopenia
were documented in 33 patients (75%) and 7 patients (16%),
respectively. Only 8 patients (18%) experienced febrile neutropenia.
Three-year progression-free survival (PFS) and overall
survival (OS) were 66% and 56%, respectively. High Ki-67
($70%) and Ann Arbor stage II independently reduced PFS
(p 5 .004) and OS (p 5 .001), respectively.
Conclusion. Due to the high rate of progression during IMEP
chemotherapy, IFRTneeds to be introduced earlier. Moreover,
active chemotherapy including an L-asparaginase-based regimen
should be use to reduce systemic treatment failure in
stage I/II NTCL. The Oncologist 2014;19:1129–1130
Department
Dept. of Internal Medicine (내과학)
Publisher
School of Medicine
Citation
TAEMIN KIM et al. (2014). A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group. Oncologist, 19(11), 1129–1130. doi: 10.1634/theoncologist.2014-0305
Type
Article
ISSN
1083-7159
DOI
10.1634/theoncologist.2014-0305
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/33602
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.